GlassScriptPhysician profile
Blake Robert Olmsted
NPI 1780948216
$8,364.17
in general payments reported to CMS, 2019-2025
33 companies · $1,825 in 2025
The $1,825 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $633 · 2021: $1,182 · 2022: $1,305 · 2023: $1,471 · 2024: $1,371 · 2025: $1,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,404 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,404.45 |
| Education | $262.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,910.34 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,364.33 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,253.51 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $738.10 | 2019-2025 | Haegarda, Andembry |
| Genentech USA, INC. | $504.39 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $435.60 | 2019-2025 | |
| Amgen INC. | $378.50 | 2022-2025 | Tezspire, Actimmune |
| Genzyme Corporation | $237.52 | 2019-2025 | |
| Kaleo, INC. | $213.79 | 2020-2023 | Auvi-Q |
| Octapharma USA, INC. | $181.21 | 2023-2025 | Cutaquig, Panzyga, Octagam Immune Globulin (Human) |
| Takeda Pharmaceuticals U.S.A., INC. | $160.12 | 2020-2025 | Takhzyro |
| Biocryst US Sales Co., LLC | $114.11 | 2021-2022 | |
| Pfizer INC. | $100.15 | 2021-2023 | |
| Optinose US, INC. | $83.14 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $82.19 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $79.27 | 2025 | Neffy |
| Uswm, LLC | $77.00 | 2021 | |
| Leo Pharma INC. | $64.32 | 2022-2024 | Adbry |
| Teva Pharmaceuticals USA, INC. | $60.07 | 2021 | |
| Ionis Pharmaceuticals, INC. | $53.92 | 2025 | Dawnzera |
| Incyte Corporation | $37.12 | 2022-2025 | Opzelura |
| Merck Sharp & Dohme LLC | $32.54 | 2023 | |
| Organon LLC | $23.24 | 2025 | |
| Sanofi-Aventis U.S. LLC | $22.27 | 2021 | |
| Paratek Pharmaceuticals, INC. | $21.65 | 2025 | Xhance |
| Verona Pharma, INC. | $21.46 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $20.95 | 2025 | Ebglyss |
| Aytu Biopharma, INC. | $19.49 | 2025 | |
| Shire North American Group INC | $18.79 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.37 | 2025 | Alvesco |
| Hikma Pharmaceuticals USA | $14.35 | 2023 | Ryaltris |
| Biocryst Pharmaceuticals, INC. | $14.06 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Olmsted listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.